Humedics appoints Erwin de Buijzer as managing director for marketing and sales
Erwin de Buijzer is a seasoned Healthcare manager with significant experience in medical marketing and strategy. He held various positions at Eurotransplant and the Dutch Transplant Foundation, as well as in medical marketing at Abbott Laboratories and Nutrica Advanced Medical Nutrition as Medical Director. Before his industry career he worked as a medical doctor in the ICU and in surgery. He received his Medical Doctor degree from the Erasmus University in Rotterdam, The Netherlands, and has an MBA from the Rotterdam School of Management.
“We are very pleased that Erwin has joined the management team of Humedics”, said Klaus Stoeckemann, Chairman of Humedics’ board and Managing Director at Peppermint VenturePartners. He brings the relevant skills and spirit to the founder team allowing to accomplishing the finalization of the FLIPTM device, the development of 13C-Methacetin and making the LiMAxTM test the standard of care in liver diagnostics”.
Based in Berlin, Germany, Humedics GmbH is specialised in rapid and accurate liver function measurement using LiMAx®, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient’s liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver.
Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis. At present, more than 20 studies regarding new indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options.
These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests. The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.